These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28792260)

  • 21. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
    Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
    Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
    Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
    Batlevi CL; Kasamon Y; Bociek RG; Lee P; Gore L; Copeland A; Sorensen R; Ordentlich P; Cruickshank S; Kunkel L; Buglio D; Hernandez-Ilizaliturri F; Younes A
    Haematologica; 2016 Aug; 101(8):968-75. PubMed ID: 27151994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
    J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
    Liu XM; Wang HQ; Zhang HL; Qiu LH; Li W; Li LF; Cui XZ; Liu PF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):779-82. PubMed ID: 19173813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
    Moskowitz CH; Bertino JR; Glassman JR; Hedrick EE; Hunte S; Coady-Lyons N; Agus DB; Goy A; Jurcic J; Noy A; O'Brien J; Portlock CS; Straus DS; Childs B; Frank R; Yahalom J; Filippa D; Louie D; Nimer SD; Zelenetz AD
    J Clin Oncol; 1999 Dec; 17(12):3776-85. PubMed ID: 10577849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
    Moskowitz CH; Yahalom J; Zelenetz AD; Zhang Z; Filippa D; Teruya-Feldstein J; Kewalramani T; Moskowitz AJ; Rice RD; Maragulia J; Vanak J; Trippett T; Hamlin P; Horowitz S; Noy A; O'Connor OA; Portlock C; Straus D; Nimer SD
    Br J Haematol; 2010 Mar; 148(6):890-7. PubMed ID: 20085577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
    Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
    Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
    Wood A; George S; Adra N; Chintala S; Damayanti N; Pili R
    Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
    Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
    Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
    Zhou P; Liu P; Zhou SY; He XH; Han XH; Qin Y; Yang S; Zhang CG; Gui L; Yao JR; Zhao LY; Zhang SX; Sun Y; Shi YK
    Chin Med J (Engl); 2015 Sep; 128(18):2498-504. PubMed ID: 26365969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.
    Fox CP; McMillan AK; Bishton MJ; Haynes AP; Russell NH
    Br J Haematol; 2008 Apr; 141(2):244-8. PubMed ID: 18353164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
    Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
    Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
    Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
    Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
    Aurer I; Mitrović Z; Nemet D; Radman I; Sertić D; Serventi-Seiwerth R; Stern-Padovan R; Santek F; Nola M; Mrsić M; Labar B
    J Chemother; 2008 Oct; 20(5):640-4. PubMed ID: 19048695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.